INTRALESIONAL ALFA-2A INTERFERON THERAPY FOR BASAL-CELL CARCINOMA

被引:15
|
作者
DOGAN, B [1 ]
HARMANYERI, Y [1 ]
BALOGLU, H [1 ]
OZTEK, I [1 ]
机构
[1] GATA HAYDARPASA TEACHING HOSP,DEPT PATHOL,ISTANBUL,TURKEY
关键词
BASAL CELL CARCINOMA; INTERFERON; TREATMENT;
D O I
10.1016/0304-3835(95)03741-E
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Basal cell carcinoma (BCC) is an epithelial tumour of the skin that arises from basal cells of the epidermis and its appendages. There are some therapeutic models for BCC, and one of these is intralesional interferon. Thirteen patients with histopathologically-proven BCC on their faces or trunk were treated with intralesional interferon alfa-2a. Only 2 of 13 patients required surgery:due to insufficient improvement. All the others were completely cured in 12 to 36 weeks. We concluded that intralesional interferon therapy of sufficient dose and duration for noduloulcerative and superficial BCC is an encouraging alternative to surgery and other treatment models.
引用
收藏
页码:215 / 219
页数:5
相关论文
共 50 条